



Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2014 Financial Results on March 12, 2015

February 26, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 26, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its fourth quarter and year-end 2014 financial results on March 12, 2015, before market open.

Following the announcement, management will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the fourth quarter results and provide operational updates.

The conference call can be accessed by dialing (877) 407-8035 (U.S.) or (201) 689-8035 (International). For those unable to join the live call, a replay will be available from noon ET on March 12 through 11:59 p.m. ET on March 19. To access the replay, please dial (877) 660-6853 (U.S.) or (201) 612-7415 (International) and refer to conference ID 13602493.

The live [webcast](#) can be accessed by visiting the [Investor Relations](#) section of the Synta Pharmaceuticals website, www.syntapharma.com. The webcast will also be archived under [Webcasts and Events](#) within the Investor Relations section of the Company's website.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that change cancer patients' lives. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

Source: Synta Pharmaceuticals Corp.

Investors:

Synta Pharmaceuticals Corp.

Daniel Cole, 781-541-7250

dcole@syntapharma.com

or

Argot Partners

Andrea Rabney, 212-600-1494

andrea@argotpartners.com

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

eliza@argotpartners.com